Hypertension is a major risk factor for morbidity and mortality. Plasma catecholamines are linked to the pathogenesis of hypertension. Pharmacological intervention, including treatment with beta-blockers, reduces cardiovascular mortality and morbidity. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the angiotensin receptor blocker losartan significantly reduced cardiovascular end points compared to the beta-blocker atenolol. Thus, for the first time, one drug was shown to be superior to another in hypertension. The present substudy examined the effects of atenolol vs losartan treatment on plasma catecholamines at rest and during hyperinsulinaemia in a cohort of 86 LIFE patients. Plasma adrenaline increased significantly from placebo treatment at baseline to year 1 of treatment (Po0.0001), and also during hyperinsulinaemia (Po0.0001). Plasma noradrenaline did not change significantly from placebo treatment at baseline to year 1, but increased significantly during hyperinsulinaemia both at baseline and at year 1 (Po0.0001 for both). There were no differences in plasma catecholamines or the relative changes between the two treatment arms at any stage. In a subset of 42 patients examined also at years 2 and 3, these findings were confirmed during long-term treatment. Thus, losartan had an effect on plasma catecholamines comparable to that with the beta-blocker atenolol in patients with hypertension and left ventricular hypertrophy at rest and during hyperinsulinaemia. We find it unlikely that a difference in sympathetic activity explains the outcome benefits of losartan over atenolol in the LIFE study.
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Introduction
Hypertension is a major risk factor for morbidity and mortality.
1,2 Plasma catecholamines are linked to the pathogenesis of hypertension.
3-8 Pharmacological intervention with beta-blockers reduces cardiovascular morbidity and mortality, 9,10 whereas results with alpha-adrenoceptor antagonists have been somewhat disappointing. 11 Until 2002, no drug or drug class had shown superiority over another in reducing cardiovascular end points; that is, all drugs reduced cardiovascular risk equally. 12 However, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the angiotensin receptor blocker losartan reduced cardiovascular end points significantly stronger than the beta-blocker atenolol despite similar blood pressure reduction in both treatment arms. 13 Thus, for the first time, one drug was shown to be superior to another in the treatment of hypertension. In substudies we have investigated possible mechanisms that can potentially explain this difference.
14 In the present prespecified LIFE substudy, we examined the treatment effect of atenolol and losartan on plasma catecholamines.
Methods

Subjects
According to a prespecified protocol in the LIFE study, 99 patients with essential hypertension and left ventricular hypertrophy were included in the Insulin Carotids US Scandinavia (ICARUS) substudy.
14 They met the LIFE inclusion and exclusion criteria, 13 and were evaluated at study baseline, after 2 weeks of placebo treatment, and after 1 year of treatment (subset 1). The patients in one centre were also studied after 2 and 3 years of treatment (subset 2). Baseline characteristics of these patients have been published previously.
14 Due to physical inability, discontinuation of randomized treatment, or inadequate catecholamine samples, 13 patients were excluded from the analyses, leaving 86 patients at baseline in the present study (subset 1). A total of 42 patients in the Oslo cohort were also investigated at years 2 and 3 (subset 2). Baseline characteristics of subsets 1 and 2 are presented in 
Catecholamine analyses
All measurements were carried out with the patient in the supine position in a quiet room with a constant temperature of 24-271C. We used handwarming to get arterialized venous blood samples. A polyethylene cannula was inserted into an antecubital vein for intermittent collection of blood samples. Blood samples for adrenaline and noradrenaline levels were taken after 30 min of supine rest and after 120 min of a hyperinsulinaemic, isoglycaemic glucose clamp examination (in subset 2 both after 60 and 120 min of the clamp), both at baseline and after 1 year of study treatment (in subset 2 also at years 2 and 3). Plasma concentrations of adrenaline and noradrenaline were determined by radioenzymatic labelling and high-pressure liquid chromatography, as previously described. 15, 16 All samples were analysed in one laboratory (Glostrup) in order to increase comparability of measurements.
Blood pressures
According to the protocol of the LIFE study, sitting blood pressure was measured at randomization and every year thereafter using a manual mercury sphygmomanometer. Furthermore, during the isoglycaemic clamp, resting blood pressure was measured with the patient in the supine position using a manual mercury sphygmomanometer or a semiautomatic device (Dinamap Model 1846 SX, Critikon, Johnson & Johnson Medical Inc., USA). Based on these blood pressure recordings, mean values for systolic and diastolic arterial blood pressure were calculated.
Hyperinsulinaemic isoglycaemic glucose clamp
A 2-h hyperinsulinaemic isoglycaemic glucose clamp was performed as previously detailed.
14 To achieve high, but physiological, insulin levels, insulin (Velosuline, Novo Nordic, Denmark) was infused for 2 h at a rate of 50 mU/m 2 /min. Isoglycaemia was maintained by infusion of glucose (200 g/l). Infusion rate was adjusted in response to plasma glucose concentrations.
Statistics
Data were analysed with SPSS version 11.0. for Windows (SPSS Inc., Chicago, IL, USA). For comparison between groups for independent samples, Student's t-test was used in normally distributed data and the Mann-Whitney test in skewed data. All catecholamine data were analysed nonparametrically. Wilcoxon's test was used to assess changes in catecholamine levels during the glucose clamp and at follow-up. The relative changes in catecholamine and blood pressure levels were calculated as ((treatment level-baseline level)/baseline level) Â 100. Differences in distribution of 
Results
Subset 1: baseline-year 1
There were no significant differences in demographic variables between the groups at baseline (Table 1) . Compared to the placebo treatment period at baseline, systolic and diastolic blood pressures were significantly lower at year 1 (Table 2) ; the differences were similar in the two treatment arms. At year 1, heart rate was significantly lower in the atenolol group and significantly higher in the losartan group (Table 2) .
Adrenaline and noradrenaline levels at rest and after 120 min of the hyperinsulinaemic, isoglycaemic, glucose clamp at baseline during placebo treatment and after one year of randomized treatment are presented in Table 3 . In the total population, adrenaline levels were significantly increased at year 1 compared to baseline levels during placebo treatment (Po0.0001), whereas noradrenaline levels were not. There were no significant differences in the levels of adrenaline or noradrenaline between the atenolol and losartan groups at baseline or during follow-up at rest or after 120 min of the glucose clamp (Table 3 ). The relative increases in adrenaline and noradrenaline levels from baseline to year 1 were not significantly different between the atenolol and losartan groups.
Compared to preclamp levels, both adrenaline and noradrenaline levels increased significantly during the glucose clamp both at baseline during placebo treatment and at year 1 ( Table 3 ). The relative increases in adrenaline and noradrenaline levels during glucose clamp were not significantly different between the atenolol and losartan groups.
Subset 2: baseline-years 1, 2, and 3
There were no significant differences in age, body mass index, cholesterol, or glucose between the treatment groups at baseline (Table 1) . Systolic and diastolic blood pressures were higher in the losartan Table 2 Blood pressure and heart rate at baseline and year 1 (subset 1) Catecholamines and treatment for hypertension E Fossum et al group compared to the atenolol group at baseline (179718/103713 vs 166714/9477 mmHg, P ¼ 0.025 and 0.031, respectively). Overall, systolic and diastolic blood pressures were significantly lower at years 1, 2, and 3 compared to baseline (Po0.0001 for all), but there were no significant differences in blood pressure levels between the groups. The relative decrease in blood pressure was significantly higher in the losartan group for systolic blood pressure at year 2 (P ¼ 0.031) and diastolic blood pressure at year 1 (P ¼ 0.017). Heart rate was not significantly different between the groups at baseline, at years 1 and 2 heart rate was significantly lower in the atenolol group (Po0.05 for both), but not significantly different at year 3.
Adrenaline and noradrenaline levels were not significantly different between the atenolol and losartan groups at baseline. Overall, adrenaline levels were significantly increased at years 1-3 compared to baseline levels (Po0.0001 for all) and noradrenaline at year 3 (Po0.05). There were no significant differences between the atenolol and losartan groups for adrenaline and noradrenaline levels at years 1-3 or the relative increase at years 1-3 for adrenaline or at year 3 for noradrenaline ( Figure 1 ).
Compared to catecholamine levels at rest at baseline and at years 1-3, both adrenaline and noradrenaline levels were significantly higher during the glucose clamp at 60 and 120 min (Po0.005 for all). There were no significant differences between the levels of adrenaline and noradrenaline in the atenolol and losartan group during clamp at baseline or at years 1-3 except for adrenaline at year 2 ( Figure 1 ). There were no significant differences in the relative increase of adrenaline and noradrenaline from rest to clamp between the atenolol and losartan groups.
Discussion
The main finding of the present study is that both the absolute levels and the relative changes of adrenaline and noradrenaline were similar during 3 years of treatment with the beta-blocker atenolol and the angiotensin receptor antagonist losartan in patients with hypertension and left ventricular hypertrophy. In a stress model known to stimulate the sympathetic nervous system (the glucose clamp), the increases in adrenaline and noradrenaline were also comparable in the two treatment arms.
Overall, adrenaline levels increased significantly from baseline to years 1-3, and noradrenaline levels from baseline to year 3. Beta-blockers may increase the levels of plasma catecholamines, either through interference with feedback mechanisms or reduced clearance. 17, 18 The increase in catecholamine levels secondary to beta-blockade is best seen during activation of the sympathetic nervous system such as during exercise or stress. 19 Angiotensin ll may also increase plasma catecholamines through interaction with the sympathetic nervous system. 20 Accordingly, AT1 receptor blockade with losartan has been shown to reduce central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. 21 However, these findings have not been confirmed in humans. Noradrenaline levels have been shown to be unaffected by losartan treatment. [22] [23] [24] During sympathetic activation, one study has shown a blunted sympathetic response to the cold pressor test during losartan treatment, 22 whereas another study did not show any effect on catecholamine levels during insulin-induced hypoglycaemia. 25 All these studies recruited small numbers of patients (less than 20) and were short lasting. [22] [23] [24] [25] Several patients included in the present study were taken off antihypertensive treatment, including different drug classes, during placebo treatment prior to randomization to losartan or atenolol. Thus, time effects may partly explain the differences between baseline levels and levels during randomized treatment. Furthermore, hydrochlorothiazide was the first add-on treatment and was given to approximately 90% of the patients. 13 Thus, the increase in catecholamine levels during the study may have multiple reasons; however, there was no difference in the response between the two treatment strategies.
Adrenaline and noradrenaline levels increased during glucose clamp both at baseline during Figure 1 Adrenaline and noradrenaline levels in subset 2 at rest and during glucose clamp. Bars represent mean and 95% confidence intervals. Solid lines ¼ atenolol, dotted lines ¼ losarlosartan. *Po0.0001 compared to levels at baseline; no significant difference between atenolol and losartan.
y Po0.05 compared to levels at baseline; no significant difference between atenolol and losartan.
# Po0.005 compared to levels at rest; no significant difference between atenolol and losartan.
þ P ¼ 0.031 for atenolol vs losartan. placebo treatment and throughout the study during randomized treatment. This might be caused by the hyperinsulinaemia. 26 However, in a study by Seljeflot et al, adrenaline and noradrenaline levels were unchanged during both an oral glucose tolerance test and a hyperinsulinaemic glucose clamp examination (except the adrenaline level after 180 minutes of the oral test) in patients with losartan as compared to placebo. 27 It has previously been shown that the clamp procedure per se, with or without insulin, activates the sympathetic nervous system due to discomfort during the procedure. 28 Thus, the clamp procedure imitates a stress test. As shown, the increase in catecholamine levels were not different between atenolol-and losartan-treated patients.
Adrenaline levels were lower in the atenolol group at year 2 during the glucose clamp compared to the losartan group. The relative reduction in systolic blood pressure from baseline to year 2 was significantly higher in the losartan group compared to the atenolol group. This might explain this difference, but most probably it is due to a chance finding or type I error.
In conclusion, losartan has a comparable effect on plasma catecholamines to the beta-blocker atenolol in patients with hypertension and left ventricular hypertrophy both at rest and during hyperinsulinaemia. We find it unlikely that a difference in sympathetic activity, as measured by plasma catecholamines, explains the outcome benefits of losartan over atenolol in the LIFE study.
